Abstract:Background and objectives: The current European Stroke Organisation expedited recommendation on tenecteplase (TNK) for acute ischemic stroke (AIS) advocates that TNK 0.25 mg/kg can be used alternatively to alteplase (tissue plasminogen activator [TPA]) for AIS of <4.5 hours duration, based on a meta-analytical approach establishing noninferiority. Since the publication of these guidelines, 4 additional randomized controlled clinical trials (RCTs) have provided further insight. Methods: We conducted an updated systematic review and meta-analysis including all available RCTs that investigated efficacy and safety of TNK 0.25 mg/kg compared with TPA for the treatment of AIS within 4.5 hours of onset. The primary outcome was defined as the excellent functional outcome at 3 months (modified Rankin Scale [mRS] score 0-1), whereas good functional outcome (mRS score 0-2), reduced disability at 3 months (≥1-point reduction across all mRS scores), symptomatic intracranial hemorrhage (sICH), and 3-month mortality were evaluated as secondary outcomes. Pooled estimates were calculated with random-effects model. A prespecified subgroup analysis was performed stratifying for TNK formulation, that is, original TNK vs biocopy: recombinant human TNK tissue-type plasminogen activator that is available in China and has a different production process. Results: Eleven RCTs were included comprising a total of 3,788 patients treated with TNK vs 3,757 patients treated with TPA. TNK was associated with higher likelihood of excellent functional outcome (risk ratio [RR] 1.05, 95% CI 1.01-1.10; p = 0.012; I2 = 0%; risk difference 2.95%; 95% CI 0.76%-5.14%; p = 0.008; I2 = 0%) and reduced disability at 3 months (common odds ratio 1.10, 95% CI 1.01-1.19; p = 0.034; I2 = 0%) compared with TPA while good functional outcome (RR 1.03, 95% CI 0.99-1.07; p = 0.142; I2 = 28%) was similar between the groups. Regarding safety outcomes, similar rates of sICH (RR 1.12, 95% CI 0.83-1.53; p = 0.456; I2 = 0%) and 3-month mortality (RR 0.97, 95% CI 0.82-1.15; p = 0.727; I2 = 12%) were observed. When stratified for TNK regimen (original vs biocopy), statistical significance in achieving an excellent functional outcome at 3 months was retained for the original TNK (RR 1.05, 95% CI 1.00-1.10; p = 0.044; I2 = 0%). Discussion: The updated meta-analysis confirms similar safety between TNK 0.25 mg/kg and TPA, while showing that TNK is superior to TPA regarding excellent functional outcome and reduced disability at 3 months. These findings support transitioning to TNK in clinical practice.

Incidence of Hemorrhage in Patients with Acute Myocardial Infarction Treated with TNK-tPA Versus Rt-Pa

Study of intravenous thrombolysis with recombinant tissue plasminogen activator(rtPA)in isolatedpenetrating artery territory infarcts

Recombinant human TNK tissue-type plasminogen activator (rhTNK-tPA) versus alteplase (rt-PA) as fibrinolytic therapy for acute ST-segment elevation myocardial infarction (China TNK STEMI): protocol for a randomised, controlled, non-inferiority trial

Effect and safety of rt-PA combined with Hydroxyethyl starch in the treatment of acute cerebral infarction

Tenecteplase versus alteplase in treatment of acute ST-segment elevation myocardial infarction: a randomized non-inferiority trial

Tenecteplase Thrombolytic Therapy for Acute Ischaemic Stroke in China: a Real-World, Multicentre, Retrospective, Controlled Study

Multi-mode MRI-based Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator(rtpa)reduces Hemorrhagic Transformation in Ischemic Stroke Patients

Effects of tirofiban on non-ST-segment elevation acute myocardial infarction

Intravenous Tenecteplase for Acute Ischemic Stroke Within 4.5-24 Hours of Onset (ROSE-TNK): A Phase 2, Randomized, Multicenter Study

Tenecteplase Reperfusion therapy in Acute ischaemic Cerebrovascular Events-II (TRACE II): rationale and design

CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke Tenecteplase II (CHABLIS-T II): rationale and design

Abstract TMP86: Effects of Tenecteplase versus Alteplase in Stroke Patients With Large Vessel Occlusions Who Achieve Full Recanalization

Intra-Arterial Local Thrombolysis for Hyperacute Cerebral Infarction with Recombinant Tissue Plasminogen Activato

Inter-arterial Thrombolysis Using Rt-Pa for Acute Cerebral Ischemic Stroke

Tenecteplase vs Alteplase in Acute Ischemic Stroke Within 4.5 Hours: A Systematic Review and Meta-Analysis of Randomized Trials

Safety of Thrombolytic Treatment Using Rt-Pa at Early Stage of Acute Cerebral Infarction

Efficacy and Safety of Tirofiban in Clinical Patients with Acute Ischemic Stroke

Application of Thrombus Aspiration Plus Tirofiban in Emergency Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction

Safety and Risk Factors Related to Hemorrhagic Complications with Tirofiban Therapy in Chinese Patients with Acute Coronary Syndrome

Thorombolytic Therapy with Rescue Percutaneous Coronary Intervention Versus Primary Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction: A Multicenter Randomized Clinical Trial

[Effect of Xingnao Kaiqiao acupuncture on safety of rt-PA intravenous thrombolysis in patients with cerebral infarction: a randomized controlled trial]